Harrow Health, Inc. – NASDAQ:HROW
Harrow Health stock price today
$37.8
+4.29
+12.84%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 16 hours
Harrow Health stock price monthly change
+41.89%
month
Harrow Health stock price quarterly change
+41.89%
quarter
Harrow Health stock price yearly change
+205.94%
year
Harrow Health key metrics
Market Cap | 1.20B |
Enterprise value | 645.08M |
P/E | -41.65 |
EV/Sales | 4.81 |
EV/EBITDA | -103.29 |
Price/Sales | 4.69 |
Price/Book | 22.79 |
PEG ratio | -1.59 |
EPS | -0.91 |
Revenue | 138.67M |
EBITDA | -1.26M |
Income | -31.33M |
Revenue Q/Q | 32.50% |
Revenue Y/Y | 49.79% |
Profit margin | -16.98% |
Oper. margin | 4.26% |
Gross margin | 71.74% |
EBIT margin | 4.26% |
EBITDA margin | -0.91% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeHarrow Health stock price history
Harrow Health stock forecast
Harrow Health financial statements
Average Price Target
$57.67
Potential upside: 52.55%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 33.47M | -4.22M | -12.64% |
|---|---|---|---|
| Sep 2023 | 34.26M | -4.39M | -12.81% |
| Dec 2023 | 36.35M | -9.14M | -25.16% |
| Mar 2024 | 34.58M | -13.56M | -39.22% |
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | |
|---|---|
| 2020 | |
| 2021 | 0.05% |
| 2022 | |
| 2023 |
| Jun 2023 | 223989000 | 201.93M | 90.15% |
|---|---|---|---|
| Sep 2023 | 286065000 | 210.66M | 73.64% |
| Dec 2023 | 311755000 | 241.75M | 77.55% |
| Mar 2024 | 295068000 | 235.33M | 79.75% |
| Jun 2023 | 4.56M | -1.24M | 189K |
|---|---|---|---|
| Sep 2023 | -1.20M | -20.13M | 64.19M |
| Dec 2023 | 8.69M | -203K | -18K |
| Mar 2024 | -4.62M | -110K | -809K |
Harrow Health alternative data
| Aug 2023 | 217 |
|---|---|
| Sep 2023 | 217 |
| Oct 2023 | 217 |
| Nov 2023 | 217 |
| Dec 2023 | 217 |
| Jan 2024 | 217 |
| Feb 2024 | 217 |
| Mar 2024 | 315 |
| Apr 2024 | 315 |
| May 2024 | 315 |
| Jun 2024 | 315 |
| Jul 2024 | 315 |
Harrow Health other data
37.38%
-26.13%
of HROW is owned by hedge funds
71
-23
10.17M
-7.11M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2023 | 25800 | 0 |
| Sep 2023 | 20000 | 0 |
| Nov 2023 | 40000 | 0 |
| Mar 2024 | 109600 | 0 |
| Apr 2024 | 69400 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | OPALEYE MANAGEMENT INC. 10 percent owner | Common Stock, par value $0.001 per share | 20,000 | $9.97 | $199,400 | ||
Purchase | OPALEYE MANAGEMENT INC. 10 percent owner | Common Stock, par value $0.001 per share | 8,285 | $10.15 | $84,093 | ||
Purchase | OPALEYE MANAGEMENT INC. 10 percent owner | Common Stock, par value $0.001 per share | 11,715 | $10.29 | $120,547 | ||
Purchase | OPALEYE MANAGEMENT INC. 10 percent owner | Common Stock, par value $0.001 per share | 29,400 | $10.56 | $310,405 | ||
Purchase | OPALEYE MANAGEMENT INC. 10 percent owner | Common Stock, par value $0.001 per share | 50,000 | $12.82 | $641,000 | ||
Purchase | BAUM MARK L director, officer.. | Common stock | 9,000 | $11.59 | $104,310 | ||
Purchase | OPALEYE MANAGEMENT INC. 10 percent owner | Common Stock, par value $0.001 per share | 50,600 | $9.65 | $488,290 | ||
Option | SAHAREK JOHN P. officer: CEO of I.. | Common stock | 5,000 | $8.75 | $43,750 | ||
Option | SAHAREK JOHN P. officer: CEO of I.. | Stock Option (Right to Buy) | 5,000 | $8.75 | $43,750 | ||
Option | SAHAREK JOHN P. officer: CEO of I.. | Common stock | 30,000 | $10.67 | $320,100 |
| Patent |
|---|
Application Filling date: 25 Sep 2019 Issue date: 2 Apr 2020 |
Application Filling date: 6 Jun 2019 Issue date: 12 Dec 2019 |
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 20 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 13 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Mark L. Baum J.D. (1973) Chief Executive Officer & Chairman | $838,300 |
Mr. Andrew R. Boll C.F.A., C.M.A., CFA, CMA (1982) Chief Financial Officer & Corporation Sec. | $574,960 |
| Mr. John P. Saharek (1960) Pres of ImprimisRx | $446,140 |
Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up
Harrow: Immense Upside Potential
Harrow: Epic Growth & Operating Leverage On Full Display
Those Derisked Baby Bonds Of Harrow, Inc.
Harrow: The Triesence Relaunch
Harrow Successfully Manufactures Triesence; Management Credibility Soars
The 'Undercovered' Dozen From May 2024
Bausch + Lomb's Bet-The-Farm Xiidra Acquisition Is Looking Questionable, But Miebo Could Make The Stock A Winner
Harrow: Merits A Buy On Sales Potential
-
What's the price of Harrow Health stock today?
One share of Harrow Health stock can currently be purchased for approximately $37.8.
-
When is Harrow Health's next earnings date?
Unfortunately, Harrow Health's (HROW) next earnings date is currently unknown.
-
Does Harrow Health pay dividends?
No, Harrow Health does not pay dividends.
-
How much money does Harrow Health make?
Harrow Health has a market capitalization of 1.20B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 46.95% to 130.19M US dollars.
-
What is Harrow Health's stock symbol?
Harrow Health, Inc. is traded on the NASDAQ under the ticker symbol "HROW".
-
What is Harrow Health's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Harrow Health?
Shares of Harrow Health can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Harrow Health's key executives?
Harrow Health's management team includes the following people:
- Mr. Mark L. Baum J.D. Chief Executive Officer & Chairman(age: 52, pay: $838,300)
- Mr. Andrew R. Boll C.F.A., C.M.A., CFA, CMA Chief Financial Officer & Corporation Sec.(age: 43, pay: $574,960)
- Mr. John P. Saharek Pres of ImprimisRx(age: 65, pay: $446,140)
-
How many employees does Harrow Health have?
As Jul 2024, Harrow Health employs 315 workers.
-
When Harrow Health went public?
Harrow Health, Inc. is publicly traded company for more then 17 years since IPO on 28 Sep 2007.
-
What is Harrow Health's official website?
The official website for Harrow Health is harrowinc.com.
-
Where are Harrow Health's headquarters?
Harrow Health is headquartered at 102 Woodmont Boulevard, Nashville, TN.
-
How can i contact Harrow Health?
Harrow Health's mailing address is 102 Woodmont Boulevard, Nashville, TN and company can be reached via phone at +61 57334730.
-
What is Harrow Health stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for Harrow Health in the last 12 months, the avarage price target is $57.67. The average price target represents a 52.55% change from the last price of $37.8.
Harrow Health company profile:
Harrow Health, Inc.
harrowinc.comExchange:
NASDAQ
Full time employees:
315
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
102 Woodmont Boulevard
Nashville, TN 37205
Nashville, TN 37205
CIK: 0001360214
ISIN: US4158581094
CUSIP: 415858109
